TLDR
- Xenon submitted a New Drug Application for azetukalner in focal seizures, marking a potential first commercial product
- The company paused new patient enrollment in major depressive disorder and bipolar depression trials due to neuropsychiatric adverse events
- XENE stock dropped 25% to $42.84 in premarket trading Friday
- Needham cut its price target to $60 from $78 but kept a Buy rating; Deutsche Bank downgraded to Hold with a $46 target
- Wells Fargo kept an Overweight rating, seeing no negative impact on the focal onset seizures indication
Xenon Pharmaceuticals filed a New Drug Application for its lead drug azetukalner in focal seizures on Thursday, a step that would bring the company its first commercial product. But the milestone was quickly overshadowed.
At the same time, Xenon announced it was pausing new patient enrollment in ongoing trials for major depressive disorder and bipolar depression. The reason: higher rates of neuropsychiatric adverse events, including confusion, somnolence, ataxia, and rare cases of psychosis.
Xenon Pharmaceuticals Inc., XENE
XENE fell 25% to $42.84 in premarket trading Friday. If those losses hold, it would be the stock’s worst single day since March 2017, when it dropped a record 53%. It would also mark the lowest close in six months.
Xenon said the adverse events were consistent with azetukalner’s known safety profile but had not shown up in earlier clinical testing. The company called the enrollment pause a likely temporary, precautionary measure.
The drugmaker said it would evaluate dosing modifications, including titration or lower doses, to improve tolerability before resuming enrollment.
Wall Street Splits on the News
Deutsche Bank analyst David Hoang downgraded XENE from Buy to Hold and slashed his price target from $90 to $46. He argued the update weakens azetukalner’s case as a leading treatment in focal epilepsy.
Wells Fargo’s Benjamin Burnett held his ground, keeping an Overweight rating. He said he sees no negative read-through for the focal onset seizures indication from the psychiatric trial pause.
Needham cut its price target from $78 to $60 but kept a Buy rating. The firm removed all major depressive disorder and bipolar disorder sales projections from its financial model for azetukalner.
Needham cited uncertainty around whether dosing modifications can reduce neuropsychiatric side effects while keeping the drug effective enough to matter.
Trial Status and Timeline
The X-NOVA2 phase 3 trial for major depressive disorder had enrolled 80% of its target 450 patients before the pause. Results are expected in the first quarter of 2027.
Xenon said it will decide whether to resume the depression and bipolar disorder trials after the X-NOVA2 readout.
H.C. Wainwright maintained a Buy rating with a $74 price target, noting there were no FDA concerns about inadequate drug exposure during a pre-NDA meeting for the epilepsy application.
Xenon holds more cash than debt on its balance sheet. InvestingPro analysis put the stock’s fair value at $52.77, suggesting it was trading above fair value even before Friday’s drop.
Analysts do not expect Xenon to be profitable this year. The stock had gained 52% over the past 12 months heading into Thursday’s news.
The revised Needham price target of $60 reflects only azetukalner’s potential in epilepsy, stripping out any value from the psychiatric indications entirely.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
